Global API manufacturer making bulk drugs, formulations and specialty chemicals across 14 plants in Gujarat, Maharashtra and Himachal Pradesh.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 23 | 93 | 93 | 93 | 92 | 91 | 91 | 91 |
| Reserves | 629 | 820 | 944 | 1.1k | 1.2k | 1.3k | 1.4k | 1.5k |
| Borrowings | 389 | 351 | 543 | 609 | 564 | 615 | 573 | 577 |
| Other Liabilities | 535 | 502 | 629 | 620 | 587 | 591 | 570 | 690 |
| Total Liabilities | 1.6k | 1.8k | 2.2k | 2.4k | 2.4k | 2.6k | 2.6k | 2.8k |
| AssetsFixed Assets | 644 | 665 | 690 | 676 | 811 | 866 | 1.1k | 1.1k |
| CWIP | 12 | 19 | 77 | 210 | 261 | 330 | 179 | 214 |
| Investments | 13 | 17 | 19 | 19 | 20 | 22 | 23 | 27 |
| Other Assets | 907 | 1.1k | 1.4k | 1.5k | 1.3k | 1.4k | 1.3k | 1.5k |
| Total Assets | 1.6k | 1.8k | 2.2k | 2.4k | 2.4k | 2.6k | 2.6k | 2.8k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 143 | 251 | 155 | 70 | 133 | 359 | 245 | 254 |
| Cash from Investing | -62 | -33 | -72 | -150 | -164 | -224 | -165 | -173 |
| Cash from Financing | -80 | -215 | -81 | 92 | 17 | -136 | -82 | -77 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 80 | 214 | 78 | -82 | -31 | 133 | 67 | 80 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (23.6×) and current (17.3×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 5.3% growth and a 17× exit, ₹370 only delivers your return if you pay ₹198. The price is currently baking in 18% growth.
EPS grows 5.3%/yr for 5 years, then fades to 6% over 2, exits at 17×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 5.3% | 22.49 |
| FY28 | 5.3% | 23.68 |
| FY29 | 5.3% | 24.94 |
| FY30 | 5.3% | 26.26 |
| FY31 | 5.3% | 27.65 |
| FY32 | 5.6% ·fade | 29.22 |
| FY33 | 6.0% ·fade | 30.97 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.